|
?:authorAffiliation
|
-
[\'Department of Biomedical Engineering, University of California, Irvine, CA, USA.\', \'Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.\', \'Vertex Pharmaceuticals, Boston, MA, USA.\', \'Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.\', \'Department of Systems Biology, Harvard Medical School, Boston, MA, USA.\', \'Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.\', \'Department of Medicine, Duke University Medical Center, Durham, NC, USA.\', \'Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC, USA.\', \'Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.\', \'Broad Institute of Harvard and MIT, Cambridge, MA, USA.\', \'Department of Medicine, Division of Infectious Diseases, Brigham and Women\'s Hospital, Boston, MA, USA.\', \'Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. andrew_kruse@hms.harvard.edu.\', \'Department of Biomedical Engineering, University of California, Irvine, CA, USA. ccl@uci.edu.\', \'Department of Chemistry, University of California, Irvine, CA, USA. ccl@uci.edu.\', \'Department of Molecular Biology & Biochemistry, University of California, Irvine, CA, USA. ccl@uci.edu.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}